Resumen

RODRIGUEZ, Ritelix et al. Eficacia del mofetil micofenolato en el tratamiento de la hepatitis autoinmune en pacientes resistentes o intolerantes a tratamiento convencional. Gen [online]. 2007, vol.61, n.3, pp.198-202. ISSN 0016-3503.

To assess the value of mycophenolate mofetil (MMF) as a therapeutic option in patients with autoimmune hepatitis (AIH), who did not respond or not tolerate prednisone and/or azathioprine. Patients and methods: Six patients with AIH were studied; age range between 36 and 61 years old, were evaluated. Initial treatment in all patients was azathioprine alone or combined with prednisone who did not demonstrate biochemical response or patients who could not tolerate this former treatment. All patients received MMF 2 g/day, 2 patients received MMF alone and 4 patients received minimal doses of steroids and MMF. Endpoints were normalization or improvement in liver function tests and immunoglobulin G (IgG) concentration. Patients were followed-up after they started treatment with MMF every 3 months during 27 μ19 months. Results: AST and ALT levels improved in 6 patients 3 to 26 times their value, and normalized in 3 patients; bilirrubin and IgG were in the normal range after treatment in all patients. Conclusions: MMF in AIH was effective and well tolerated and all patients showed improvement in liver function test (AST, ALT, and TB) and normalization of IgG. MMF seems to be an alternative treatment in selected patients with AIH.

Palabras clave : Autoimmune Hepatitis (AIH); Mycophenolate Mofetil (MMF).